Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
Lumakras (sotorasib) | Lung Cancer

FDA Approves First Targeted Therapy for Lung Cancer with Specific Genetic Mutation

Posted on May 31, 2021
Post Views: 341

Lumakras (sotorasib) | Lung CancerThe U.S. Food and Drug Administration has approved Lumakras (sotorasib) as first treatment for non-small cell lung cancer patients whose tumors have specific type of genetic mutation called KRAS G12C. It is the first drug approved to treat KRAS-G12C which is a common mutation that researchers have struggled over the years to target. Amgen said that about 13% of people in USA with non-small cell lung cancer or about 25000 patients annually have the KRAS mutation that Lumakras treats.

This medication is designed to target a gene mutation which is called KRAS G12C. KRAS is a type of mutation in a group of genes that help to regulate cell growth. The researchers have evaluated the efficacy of Lumakras in a study of 124 patients with locally advanced or metastatic KRAS G12C-mutated NSCLC with disease progression after receiving an immune checkpoint inhibitor.

Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA’s Center for Drug Evaluation and Research said, “KRAS mutations have long been considered resistant to drug therapy, representing a true unmet need for patients with certain types of cancer.” “Today’s approval represents a significant step towards a future where more patients will have a personalized treatment approach,” he added.

Lumakras (sotorasib) | Lung CancerThis FDA approved drug by Amgen, sotorasib, will be sold under the brand name Lumakras and helped to shrink tumors with KRAS mutation in about 36% of patients in clinical trials. Amgen said that the drug will have U.S list price of $17900 per month. This approval is for a daily 960 milligram pill and is based on available clinical data as well as pharmacokinetic and pharmacodynamic modeling that support the approved dose.

The common side effects that come with Lumakras are diarrhea, nausea, liver damage, musculoskeletal pain, and cough. This approval is the latest advance from cancer research field that delivered many new targeted therapies over the past few years.

 

The information shared in this blog is solely for educational purposes and is certainly not a substitute for medical advice.

 

Subscribe to our newsletter or follow us on Twitter or Facebook today and never miss an update!

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram

Like this:

Like Loading...

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,325)
  • Lung Cancer: Symptoms and Treatment (5,657)
  • What is Non-Small-Cell Lung Cancer? (5,554)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • Study: Wildfire Smoke Exposure Affects Lung Cancer Survival June 2, 2025
  • Predicting Lung Cancer Risk with AI based Deep Learning Model May 26, 2025
  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025
  • Origins of Common Lung Cancer Linked to Smoking Discovered May 5, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha.
  • Privacy Policy
  • About Us
  • Sitemap
  • Contact Us
%d